Search

Thanks to support from Roche Molecular Diagnostics and Intralytix, ASM Division M will provide 4 travel awards to students presenting phage work at ASM Microbe 2019! To apply, use "phage" as a keyword in your submitted abstract. Before you

Due to the partial U.S. government shutdown, ASM is extending the deadline for ASM Microbe abstract submissions to January 25, 2019.

A phase II clinical trial for a phage lysin has been deemed successful! An anti-Staphylococcus aureus phage lysin, called exebacase, was just found to be both safe and effective at treating MRSA in patients. Exebacase is being developed by

IPATH has just received FDA approval to start its first clinical trial! This will be the first US trial involving intravenous (IV) phage treatment, and will be a collaboration with Ampliphi Biosciences.

Johnson & Johnson has invested $20 million (with another ~$800 million to follow if things go well) into Locus Biosciences, a biotech company equipping phages with CRISPR-Cas3 to obliterate bacterial DNA upon phage infection.

Bioharmony Therapeutics and Boehringer Ingelheim just announced a collaboration to develop Acinetobacter baumannii lysin therapeutics.

CBC has provided a Canadian perspective on phage therapy (and there's a Quirks and Quarks radio show linked in the article!)

Jee-Hwan Oh and colleagues published a paper on how certain dietary sugars promote Lactobacillus phage production in the mouse gut.

Our opinion piece, A Bright Outlook for Bacteriophage Applications, is featured in the Microbiome Times January 2019 edition (page 34).

Want to win one of 50 free copies of The Perfect Predator, the true story of how a global village saved the life of Tom Patterson with IV phage therapy? Sign up for the book giveaway on Goodreads.com by Jan 23. Note: you need to view it fro

Phages for Global Health reached their 2018 fundraising goal, meaning they can deliver TWO phage workshops in 2019! Congratulations! And thanks to everyone who supports this one-of-a-kind phage nonprofit! Donate or sign up for their newslet

PharmExec.com has named phage therapy as one of the top 10 drug discovery trends to watch in 2019!

Dr. Saima Aslam and colleagues at IPATH / UCSD School of Medicine and Ampliphi Biosciences report on their use of IV phage therapy to treat biofilms associated with left ventricular assist devices (LVADs). This is now a protocol guiding cli

Could phages help explain the mysteriously healing qualities of India's Ganges river? If you're looking to learn about some interesting phage-related history (and mystery), you may like this excerpt of the new book "Ganges: The Many Pasts O

Mt. Sinai Hospital in NYC is now recruiting patients for a randomized, controlled, double-blind, Phase 1/2a phage therapy trial. The goal: test the safety and efficacy of Intralytix's EcoActive phage collection on intestinal AIEC (adherent

Phage scientists! It's time for the International Society for Viruses of Microorganisms (ISVM) elections. If you're a member, you can run for: President-elect, Vice-President, Secretary, Secretary Assistant, Treasurer, or Private Partnershi

Bacteria sometimes acquire "incorrect" CRISPR spacers in response to phage infection. Until now, no one knew whether these incorrect ("slipped") spacers had a purpose. Simon A. Jackson, Peter Fineran and co. have just shown that slipped spa

Ampliphi Biosciences just published new pre-clinical data on its anti-Staphylococcus aureus phage cocktail.

A perspective on phage therapy as an anti-superbug option in India.

NIAID just issued a request for comments and suggestions on its Antibacterial Resistance Research Framework. Details: NIAID laid out 7 approaches for tackling AMR in 2014 (including exploring phage therapy!), and they're updating these appr